EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting CD44 and other pleiotropic co-receptors as a means for broad inhibition of tumor growth and metastasis

Lisa-Marie Mehner, Leonel Munoz-Sagredo, Steffen Joachim Sonnentag, Sven Máté Treffert, Véronique Orian-Rousseau iD

Clinical & Experimental Metastasis · 2024

DOI: 10.1007/s10585-024-10292-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical & Experimental Metastasis, 2024. Verfasst von Lisa-Marie Mehner und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biological and Chemical Systems - Functional Molecular Systems, Karlsruhe Institute of Technology, Karlsruhe, Germany. Hauptthemen laut MEDLINE: Neoplasms, Hyaluronan Receptors, Signal Transduction. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karlsruher Institut für Technologie (KIT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although progress has been made in the treatment of cancer, particularly for the four major types of cancers affecting the lungs, colon, breast and prostate, resistance to cancer treatment often emerges upon inhibition of major signaling pathways, which leads to the activation of additional pathways as a last-resort survival mechanism by the cancer cells. This signaling plasticity provides cancer cells with a level of operational freedom, reducing treatment efficacy. Plasticity is a characteristic of cancer cells that are not only able to switch signaling pathways but also from one cellular state (differentiated cells to stem cells or vice versa) to another. It seems implausible that the inhibition of one or a few signaling pathways of heterogeneous and plastic tumors can sustain a durable effect. We propose that inhibiting molecules with pleiotropic functions such as cell surface co-receptors can be a key to preventing therapy escape instead of targeting bona fide receptors. Therefore, we ask the question whether co-receptors often considered as “accessory molecules” are an overlooked key to control cancer cell behavior.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHyaluronan ReceptorsSignal TransductionHumansNeoplasm MetastasisAnimalsAntineoplastic AgentsMolecular Targeted Therapy

Stichwörter der Autor:innen

CD44CancerCo-receptorsMetastasisPleiotropicity

Substanzen

Hyaluronan ReceptorsAntineoplastic AgentsCD44 protein, human

Autor:innen und Institutionen

  • Institute of Biological and Chemical Systems - Functional Molecular Systems, Karlsruhe Institute of Technology, Karlsruhe, Germany.
  • School of Medicine, Universidad de Valparaiso, Valparaiso, Chile.
  • Institute of Biological and Chemical Systems - Functional Molecular Systems, Karlsruhe Institute of Technology, Karlsruhe, Germany. veronique.orian-rousseau@kit.edu.

ORCID-Profile: Véronique Orian-Rousseau

Förderung

  • Karlsruher Institut für Technologie (KIT)

Zitieren

APA

Mehner, L. M., Munoz-Sagredo, L., Sonnentag, S. J., Treffert, S. M., & Orian-Rousseau, V. (2024). Targeting CD44 and other pleiotropic co-receptors as a means for broad inhibition of tumor growth and metastasis. Clinical & Experimental Metastasis. https://doi.org/10.1007/s10585-024-10292-4

Vancouver

Mehner LM, Munoz-Sagredo L, Sonnentag SJ, Treffert SM, Orian-Rousseau V. Targeting CD44 and other pleiotropic co-receptors as a means for broad inhibition of tumor growth and metastasis. Clinical & Experimental Metastasis. 2024. doi:10.1007/s10585-024-10292-4

BibTeX
@article{Mehner2024,
  author = {Mehner, Lisa-Marie and Munoz-Sagredo, Leonel and Sonnentag, Steffen Joachim and Treffert, Sven Máté and Orian-Rousseau, Véronique},
  title = {Targeting CD44 and other pleiotropic co-receptors as a means for broad inhibition of tumor growth and metastasis},
  journal = {Clinical & Experimental Metastasis},
  year = {2024},
  doi = {10.1007/s10585-024-10292-4}
}
Kostenlos starten →